Phase 4 N=246 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)
Malaria,Falciparum
Primary: Incidence of Clinical Malaria Per Patient Year — 0.04; 3.05; 1.36 episodes/patient year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
SARS-CoV-2 Infection
Primary: Safety of Treatment With High-titer Anti-SARS-CoV-2 Plasma as Assessed by Adverse Events — 0 Participants
N/A N=200 Multiple Cardiac Sensors for the Management of Heart Failure
Heart Failure, Congestive
Primary: Manage-HF Phase I — 191 Participants
Phase 2 N=4 A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
Myelodysplastic Syndromes
Primary: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
N/A N=351 Effects of Exemestane on Bone Strength
Osteoporosis · Breast Cancer
Primary: Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24…
N/A N=34 Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)
Medication Adherence · Depressive Symptoms · Anxiety Symptoms
Primary: Antiretroviral (ART) Medication Use — .94 units on a scale
N/A N=14 Rutgers Pilot for PREDICT- Patient POC Test
SARS CoV 2 Infection
Primary: Patient Willingness to Follow Through With the Study Surveys, Triage and Testing — 71.42 percentage of participants
Phase 4 N=55 Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
Nail Psoriasis · Nail Diseases
Primary: Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis — 2.5 mg/mL
Phase 2 N=18 Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus
Primary: Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL — 5019.6; 4591.9; 13317.5 min*mg/dL — p=<0.0001
Phase 2 N=24 A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
GastroEsophageal Cancer · Gastric Cancer
Primary: Overall Response Rate — 25 percentage of participants
Phase 2 N=23 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
Rett Syndrome
Primary: Dose-Limiting Adverse Events — 2; 4; 6; 3 Participants
Phase 1 N=32 Effect of a Ghrelin Receptor Agonist on Muscle and Bone
Sarcopenia · Osteopenia
Primary: Total Body Muscle Mass — 21.8; 20.8; 22.2; 20.8 kg units on a scale
N/A N=153 Improving the Recovery and Outcome Every Day After the ICU
Delirium · Alzheimer Disease
Primary: Cognitive Status Outcome at 6 Months — 0.24; 0.36; 0.21; 0.35 Z-score — p=0.747
N/A N=70 Battlefield Auricular Acupuncture for Control of Post-partum Pain
Pain
Primary: Number of Subjects Who Achieved 50% Sustained Pain Reduction — 0; 0; 2; 6 # of subjects with 50% pain reduction
N/A N=112 VR Intervention to Improve Police Safety
Autism Spectrum Disorder · Autism
Primary: Change in Live or Virtual Police Interaction Assessment Scores From Pre-to-Post Treatment — .13; .29; -.28; .02 Change from baseline - units on a scale — p=.23